Search...
Gao Hongmei, a director of BIOTEST BIOTECH, completed a reduction in holdings, with a total reduction of 560,000 shares
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, BIOTEST BIOTECH announced that the share reduction plan of the company's director and senior management Gao Hongmei has been completed, with a total of 560,000 shares sold through centralized bidding, accounting for 0.5250% of the company's total share capital
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments